MCE - Delayed Quote EUR

Grifols, S.A. (GRF.MC)

9.06

-0.05

(-0.57%)

At close: January 10 at 5:41:17 PM GMT+1

Exploring Three High Growth Tech Stocks For Future Potential

As global markets navigate a mixed economic landscape marked by declining consumer confidence and fluctuating indices, technology stocks continue to capture attention with their potential for high growth. In this environment, identifying promising tech stocks involves assessing factors such as innovation, market demand, and the ability to adapt to changing economic conditions.

Simply Wall St. 10 days ago

GIFLF

GIFOF

GIKLY
Exploring High Growth Tech Stocks This December 2024

As global markets reach new heights, with indices like the Russell 2000 hitting record intraday highs, investor sentiment remains buoyed by domestic policy developments and easing geopolitical tensions. In this environment, identifying high-growth tech stocks that can capitalize on current economic trends and technological advancements is crucial for investors seeking to navigate the evolving landscape of December 2024.

Simply Wall St. last month

GIFLF

GIFOF

GIKLY
Sector Update: Health Care Stocks Slipping Late Afternoon

Health care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health

PREMIUM
MT Newswires last month

PTCT

SNTI

NVS
Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?

On Wednesday, Grifols SA (NASDAQ:GRFS) said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition. This decision follows the company’s November 19 statement rejecting Brookfield’s indicative offer to acquire Grifols for 6.45 billion euros ($6.81 billion) or 10.50 euros per Class A share. Canadian fund Brookfield said it had dropped its plan to take over Spain’s Grifols due to a disagreement over the pharmaceutical company’s value, while Grifols said it

Benzinga last month

GRFS
Grifols Stock Declines After Brookfield Drops Buyout Offer

Brookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation.

Zacks last month

GRFS

BAM

SPRO
Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Health care stocks were higher late Wednesday afternoon, with the NYSE Health Care Index and the Hea

PREMIUM
MT Newswires last month

GRFS

BAM
Top Midday Decliners

Symbotic (SYM) said it submitted a notification of late filing for its annual report for the fiscal

PREMIUM
MT Newswires last month

GRFS

SYM
Update: Market Chatter: Grifols' Family Won't Welcome Other Takeover Bids as Brookfield Walks Away

(Updates with Brookfield statement in the second paragraph.) Grifols (GRFS) has decided not to we

PREMIUM
MT Newswires last month

GRFS

BAM
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday

Health care stocks rose premarket Wednesday as the Health Care Select Sector SPDR Fund (XLV) advance

PREMIUM
MT Newswires last month

GRFS

OTLK
Market Chatter: Brookfield Set to Drop Grifols Bid as Family Shuns Others

Brookfield Asset Management Ltd. is preparing to walk away from a plan to acquire Grifols SA over di

PREMIUM
MT Newswires last month

GRFS

BAM
Market Chatter: Grifols' Family Won't Welcome Other Takeover Bids as Brookfield Walks Away

Grifols (GRFS) has decided not to welcome a new takeover bid by a third-party as Brookfield Asset Ma

PREMIUM
MT Newswires last month

GRFS

BAM
Grifols shares tumble after Brookfield drops takeover plan

MADRID (Reuters) -Canadian fund Brookfield said on Wednesday it has dropped its plan to take over Spain's Grifols due to a disagreement over the pharmaceutical company's value, while Grifols said it concurred with the decision. Brookfield had filed a non-binding offer on Nov. 19 for Grifols that valued the developer of human plasma-based drugs at 6.45 billion euros ($6.79 billion), which Grifols then said was a significantly undervalued offer and told its shareholders to stick to their shares. Grifols shares closed 9.07% down on Wednesday after falling more than 12% in earlier trading after Bloomberg first reported Brookfield's decision.

Reuters last month

GRFS
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.

Zacks last month

GRFS

BAM

CTMX
GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment

The potency of GIGA-2339 is claimed to be more than 2,000 times greater than that of plasma-derived HBV treatments.

Clinical Trials Arena last month

GRFS
Grifols: Brookfield's potential $6.8 billion offer undervalues the firm

MADRID (Reuters) -Grifols said on Tuesday that Canadian investment fund Brookfield's potential 6.45 billion euro ($6.8 billion) offer significantly undervalued the Spanish drugmaker's prospects and long-term potential, telling shareholders to stick to their shares. Earlier on Tuesday, Brookfield said it was considering a public offer for Grifols at 10.50 euros per A share and 7.62 euros per B share, implying a company valuation of 6.45 billion euros. The proposal is non-binding, Brookfield said in a filing to the Spanish stock market regulator.

Reuters last month

GRFS
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus

GIGA-2339 contains more than 1,000 fully human recombinant anti-HBV antibodies and is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic HBV infectionSAN CARLOS, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a subsidiary of Grifols, announced today that the first patient has been dosed in a Phas

GlobeNewswire last month

GIFLF

GIFOF

GIKLY
Market Chatter: Canada's Brookfield Reportedly Plans to Offer About 7-billion Euros For Spanish drugmaker Grifols

Market Chatter: Canada's Brookfield Reportedly Plans to Offer About 7-billion Euros For Spanish drugmaker Grifols

PREMIUM
MT Newswires last month

GRFS
Grifols SA (GIFLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Cash ...

Grifols SA (GIFLF) reports a 12.4% revenue increase and significant EBITDA improvement, while navigating financial expenses and market challenges.

GuruFocus.com 2 months ago

GRFS
High Growth Tech Stocks to Watch in November 2024

As global markets react to rising U.S. Treasury yields and a tempered outlook for Federal Reserve rate cuts, small-cap stocks have felt the pressure more acutely than their large-cap counterparts. In this environment, identifying promising high-growth tech stocks involves looking for companies that demonstrate resilience through innovation and adaptability to shifting economic conditions.

Simply Wall St. 2 months ago

GIFLF

GIFOF

GIKLY
Grifols And 2 Other Stocks That Might Be Trading Below Estimated Value

As global markets grapple with rising Treasury yields and tepid economic growth, investors are increasingly focused on identifying stocks that may be trading below their intrinsic value. In this environment, a good stock is often characterized by strong fundamentals and the potential for future growth, making it an attractive option for those seeking value amidst market fluctuations.

Simply Wall St. 2 months ago

GIFLF

GIFOF

GIKLY

Performance Overview

Return	GRF.MC	IBEX 35...
YTD	-1.37%	+1.60%
1-Year	-14.14%	+16.51%
3-Year	-44.14%	+33.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Grifols, S.A. (GRF.MC)

Exploring Three High Growth Tech Stocks For Future Potential

Exploring High Growth Tech Stocks This December 2024

Sector Update: Health Care Stocks Slipping Late Afternoon

Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?

Grifols Stock Declines After Brookfield Drops Buyout Offer

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Top Midday Decliners

Update: Market Chatter: Grifols' Family Won't Welcome Other Takeover Bids as Brookfield Walks Away

Sector Update: Health Care Stocks Rise Pre-Bell Wednesday

Market Chatter: Brookfield Set to Drop Grifols Bid as Family Shuns Others

Market Chatter: Grifols' Family Won't Welcome Other Takeover Bids as Brookfield Walks Away

Grifols shares tumble after Brookfield drops takeover plan

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment

Grifols: Brookfield's potential $6.8 billion offer undervalues the firm

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus

Market Chatter: Canada's Brookfield Reportedly Plans to Offer About 7-billion Euros For Spanish drugmaker Grifols

Grifols SA (GIFLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Cash ...

High Growth Tech Stocks to Watch in November 2024

Grifols And 2 Other Stocks That Might Be Trading Below Estimated Value

Performance Overview